2. Search Result
Search Result
Results for "

reducing pain

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0273
    Propyphenazone

    4-Isopropylantipyrine; Isopropylphenazone

    		 COX Inflammation/Immunology
    Propyphenazone (4-Isopropylantipyrine) is an orally active nonacidic pyrazole nonsteroidal anti-inflammatory drug (NSAID). Propyphenazone is a weak nonselective COX inhibitor. Propyphenazone has the effect of reducing pain and antipyretic activity with minimal anti-inflammatory activity .
    Propyphenazone
  • HY-B1183
    Hydrocortisone acetate
    1 Publications Verification

    Hydrocortisone 21-acetate; Cortisol 21-acetate

    		 Glucocorticoid Receptor Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology
    Hydrocortisone acetate (Hydrocortisone 21-acetate) is a corticosteroid used to reduce swelling, itching and pain caused by minor skin irritations or hemorrhoids .
    Hydrocortisone acetate
  • HY-A0273R
    Propyphenazone (Standard)

    		COX Inflammation/Immunology
    Propyphenazone (Standard) is the analytical standard of Propyphenazone. This product is intended for research and analytical applications. Propyphenazone (4-Isopropylantipyrine) is an orally active nonacidic pyrazole nonsteroidal anti-inflammatory drug (NSAID). Propyphenazone is a weak nonselective COX inhibitor. Propyphenazone has the effect of reducing pain and antipyretic activity with minimal anti-inflammatory activity .
    Propyphenazone (Standard)
  • HY-P3517
    β-Endorphin (6-31), human

    β-EP (6-31), human

    		 Opioid Receptor Neurological Disease Endocrinology
    β-Endorphin, an endogenous opioid neuropeptide, is an opioid receptor agonist. β-Endorphin binds preferentially to μ-opioid receptors and is produced in certain neurons of the central and peripheral nervous system and is one of three endorphins produced in humans. β-Endorphin can be used to reduce stress and maintain homeostasis in the body and is involved in neurological pain perception regulation .
    β-Endorphin (6-31), human
  • HY-124406
    A-794282

    		mGluR Neurological Disease
    A-794282 is an antagonist with analgesic activity, selectively targeting to mGlu1 receptor that significantly reduces pain behaviors in a postoperative pain model, but motor side effects may occur at higher doses .
    A-794282
  • HY-149863
    DDO-8926

    		Epigenetic Reader Domain Neurological Disease
    DDO-8926 is a potent and selective BET inhibitor that can significantly reduce mechanical hypersensitivity by inhibiting the expression of pro-inflammatory cytokines and reducing excitability for neuropathic pain research .
    DDO-8926
  • HY-10635
    ABT-102

    		TRP Channel Inflammation/Immunology Cancer
    ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain .
    ABT-102
  • HY-106325
    AA 2379

    		Phosphodiesterase (PDE) Inflammation/Immunology
    AA 2379 is an orally active antirheumatic agent. AA 2379 has antiinflammatory, antipyretic activities and reduces pain sensation .
    AA 2379
  • HY-14742
    Faxeladol

    		Others Others
    Faxeladol is a compound with analgesic activity that reduced mean pain intensity compared with placebo in a suppression trial for painful polyneuropathy with a favorable safety profile.
    Faxeladol
  • HY-145726
    ISIS 104838

    		TNF Receptor Inflammation/Immunology
    ISIS 104838 is an antisense oligonucleotide agent that reduces the production of tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain and swelling in rheumatoid arthritis.
    ISIS 104838
  • HY-145726A
    ISIS 104838 sodium

    		TNF Receptor Inflammation/Immunology Cancer
    ISIS 104838 sodium is an antisense oligonucleotide agent that reduces the production of tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain and swelling in rheumatoid arthritis.
    ISIS 104838 sodium
  • HY-106199
    Adenosine A1 receptor activator T62
    1 Publications Verification

    		 Adenosine Receptor Neurological Disease Inflammation/Immunology
    Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain .
    Adenosine A1 receptor activator T62
  • HY-B0641
    Felbinac

    4-Biphenylacetic acid

    		 COX Inflammation/Immunology
    Felbinac is a metabolite of fenbufen, an orally active nonsteroidal anti-inflammatory agent and a cyclooxygenase (COX) inhibitor with an IC50 of 865.68 nM for COX1 and 976 nM for COX2. Felbinac reduces the production of prostaglandins by inhibiting COX to relieve pain, reduce inflammation and reduce fever. Felbinac can inhibit CHIKV viral activity .
    Felbinac
  • HY-P0062
    Ziconotide

    SNX-111

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide (SNX-111), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide
  • HY-P0062B
    Ziconotide acetate

    SNX-111 acetate

    		 Calcium Channel Cardiovascular Disease Inflammation/Immunology Cancer
    Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide acetate
  • HY-W105835
    Magnesium citrate

    Trimagnesium dicitrate

    		 Toll-like Receptor (TLR) Neurological Disease
    Magnesium citrate is a magnesium salt form that provides efficient penetration into brain and muscle tissue. Magnesium citrate increases pain threshold and reduces TLR4 concentration in the brain. Orally active .
    Magnesium citrate
  • HY-N2258
    Poncirin
    1 Publications Verification

    		 Apoptosis Inflammation/Immunology
    Poncirin is isolated from?Poncirus trifoliata with anti-inflammory activites. Poncirin significantly reduces mechanical hyperalgesia and allodynia in Complete Freund’s Adjuvant (CFA)-induced inflammatory pain models .
    Poncirin
  • HY-13283
    MF63
    1 Publications Verification

    		 PGE synthase Inflammation/Immunology
    MF63 is a selective and orally active inhibitor of mPGES-1. MF63 reduces the accumulation of PGE2, relieves pyresis, hyperalgesia, and inflammatory pain by inhibiting mPGES-1 .
    MF63
  • HY-147732
    sEH inhibitor-4

    		Epoxide Hydrolase Inflammation/Immunology
    Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.
    sEH inhibitor-4
  • HY-P0062A
    Ziconotide TFA

    SNX-111 TFA

    		 Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of N-type calcium channels antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .
    Ziconotide TFA
  • HY-121103
    Aclantate

    		Histone Methyltransferase Inflammation/Immunology
    Aclantate is a nonsteroidal anti-inflammatory drug with anti-inflammatory and analgesic activity. Aclantate is mainly used to relieve various types of pain and reduce inflammatory responses. Aclantate can be used to suppress rheumatoid arthritis and other related diseases .
    Aclantate
  • HY-110099
    (±)-NBI-74330

    		CXCR Inflammation/Immunology
    (±)-NBI-74330 is a potent and selective CXCR3 antagonist. (±)-NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±)-NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model .
    (±)-NBI-74330
  • HY-14886
    Fasitibant chloride

    MEN16132 free base

    		 Bradykinin Receptor Cardiovascular Disease Neurological Disease
    Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model .
    Fasitibant chloride
  • HY-159924
    DBPR116

    		Opioid Receptor Neurological Disease
    DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic .
    DBPR116
  • HY-103344
    ZJ43

    		Aminopeptidase mGluR Neurological Disease Inflammation/Immunology
    ZJ43 is a potent NAAG peptidase inhibitor, with an IC50 of 2.4 nM and a Ki of 0.8 nM. ZJ43 sufficiently activates group II mGluR and reduces some of the behavioral effects of PCP. ZJ43 shows an analgesic effect in neuropathic and inflammatory and pain models .
    ZJ43
  • HY-169223
    Roxatidine hydrochloride

    		Others Endocrinology
    Roxatidine hydrochloride is an anti-ulcer compound with the activity of inhibiting gastric acid secretion. Roxatidine hydrochloride effectively inhibits duodenal and gastric ulcers and reduces ulcer pain. Roxatidine hydrochloride has a better safety profile than other similar compounds due to the lower dose required for effective inhibition .
    Roxatidine hydrochloride
  • HY-B0193
    Prazosin
    Maximum Cited Publications
    12 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Prazosin is an α-adrenergic receptor antagonist. Prazosin can reduce inflammation, relieve anxiety, alleviate panic, prevent memory decline, and modulate the pain-relieving effects of opioids. Prazosin can be used in the study of hypertension and Alzheimer’s disease .
    Prazosin
  • HY-120546
    Ulixacaltamide

    Z944; PRAX-944

    		 Calcium Channel Neurological Disease Inflammation/Immunology
    Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .
    Ulixacaltamide
  • HY-N2258R
    Poncirin (Standard)

    		Apoptosis Inflammation/Immunology
    Poncirin (Standard) is the analytical standard of Poncirin. This product is intended for research and analytical applications. Poncirin is isolated from Poncirus trifoliata with anti-inflammory activites. Poncirin significantly reduces mechanical hyperalgesia and allodynia in Complete Freund’s Adjuvant (CFA)-induced inflammatory pain models .
    Poncirin (Standard)
  • HY-P10767
    MD01-67

    		Neurotensin Receptor Neurological Disease
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models .
    MD01-67
  • HY-124996
    (Rac)-ZLc-002

    		NO Synthase Neurological Disease Inflammation/Immunology Cancer
    (Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability .
    (Rac)-ZLc-002
  • HY-107510
    YM-230888

    		mGluR Neurological Disease
    YM-230888 is an orally active, selective and allosteric mGlu1 receptor antagonist with a Ki of 13 nM. YM-230888 inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 13 nM. YM-230888 shows antinociceptive response in Streptozotocin (HY-13753)-induced hyperalgesia models. YM-230888 significantly reduces pain parameters in complete Freund's adjuvant (HY-153808)-induced arthritic pain models .
    YM-230888
  • HY-128794
    PF-05150122

    		Others Neurological Disease
    PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential .
    PF-05150122
  • HY-N12777
    Coixenolide

    		Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    Coixenolide can be isolated from coix seeds, and exhibits anti-inflammatory, anti-tumor and pain-reducing activities. Coixenolide stimulates the lung, heart, striated and smooth muscles at low doses, while inhibits at high doses. Coixenolide dilates pulmonary veins and improves pulmonary blood circulation .
    Coixenolide
  • HY-164803
    CBD3063

    		Calcium Channel Inflammation/Immunology
    CBD3063 is a selective modulator of collapsin response mediator protein 2 (CRMP2). CBD3063 uncouples Cav2.2 from CRMP2. CBD3063 reverses neuropathic and inflammatory pain by reducing membrane expression of CaV2.2 .
    CBD3063
  • HY-B0317F
    Amlodipine hydrochloride

    		Calcium Channel Infection
    Amlodipine hydrochloride is a biologically active drug used to lower blood pressure and prevent chest pain. Amlodipine hydrochloride has shown synergistic effects with antimicrobial drugs in in vitro studies, especially against carbene peptide-resistant Acinetobacter baumannii. Amlodipine hydrochloride can be used in combination with other antibiotics to enhance the inhibitory effect against resistant bacteria. The use of amlodipine hydrochloride helps reduce the dosage requirements of the drug, reduce toxic effects, and delay the emergence of drug resistance .
    Amlodipine hydrochloride
  • HY-W357818
    Glycinexylidide

    GX

    		 Sodium Channel ERK MEK NF-κB Drug Metabolite Cancer
    Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .
    Glycinexylidide
  • HY-143880
    MRGPRX1 agonist 4

    		Mas-related G-protein-coupled Receptor (MRGPR) Neurological Disease
    MRGPRX1 agonist 4 (compound 1t) is a potent and orally active Mas-related G protein-coupled receptor X1 (MRGPRX1) positive allosteric modulator with an EC50 value of 0.1 μM. MRGPRX1 agonist 4 has good metabolic stability and oral bioavailability. MRGPRX1 agonist 4 can reduce behavioral heat hypersensitivity in a neuropathic pain model humanized MRGPRX1 mice. MRGPRX1 agonist 4 can be used for researching neuropathic pain .
    MRGPRX1 agonist 4
  • HY-167862
    UCM-05194

    		Others Neurological Disease
    UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .
    UCM-05194
  • HY-115510
    SPR inhibitor 3

    SPRi3

    		 Others Inflammation/Immunology
    SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC50=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC50=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels .
    SPR inhibitor 3
  • HY-121886
    Bucricaine

    		Endogenous Metabolite Neurological Disease
    Bucricaine is an anesthetic compound with analgesic activity. Bucricaine is used in clinical anesthesia to reduce pain during surgery. The mechanism of action of Bucricaine involves inhibition of nerve signaling. Bucricaine's applications include local anesthesia and dental anesthesia. Bucricaine is widely used during surgery and other medical procedures to improve patient comfort .
    Bucricaine
  • HY-119097
    LY456066

    		mGluR Neurological Disease
    LY456066 is a selective non-competitive metabotropic glutamate receptors (mGluR1) antagonist with an IC50 value of 52.0 nM. LY456066 is effective in rodent models of anxiolysis and nociception. LY456066 reduces hyperalgesia and the amount of licking and flinching following formalin injection, which is promising for research of analgesics for chronic pain .
    LY456066
  • HY-14380
    PF-3845
    1 Publications Verification

    		 FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
    PF-3845
  • HY-121974
    SR14150

    		Others Neurological Disease
    SR14150 is a partial agonist of the NOP receptor with high affinity. The biological activity of SR14150 makes it potentially useful for the development of a new generation of multi-target opioids designed to simultaneously improve analgesia and reduce side effects. The activity of SR14150 and its interaction with other opioid receptors may provide new inhibitory options for the management of chronic pain .
    SR14150
  • HY-107794
    Clodronate disodium tetrahydrate
    2 Publications Verification

    Disodium clodronate tetrahydrate

    		 Others Neurological Disease Inflammation/Immunology Cancer
    Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl - competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain .
    Clodronate disodium tetrahydrate
  • HY-167855
    MRS4833

    		P2Y Receptor Inflammation/Immunology
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
    MRS4833
  • HY-B0561
    Spironolactone
    3 Publications Verification

    SC9420

    		 Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (AngⅡ)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type Ⅱ diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone
  • HY-116005
    A-286501

    		Adenosine Kinase Neurological Disease Inflammation/Immunology
    A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC50 value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .
    A-286501
  • HY-13954
    A 839977
    1 Publications Verification

    		 P2X Receptor Neurological Disease Inflammation/Immunology
    A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
    A 839977
  • HY-127110
    AK106-001616

    		Phospholipase Others Neurological Disease Inflammation/Immunology
    AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .
    AK106-001616

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: